There’s more to read into David’s email to me
1) note that Sareptas had 4 drugs approved without reaching endpoints and they did not show clinical benefits re DMD ..
2) David said FDA were happy with the secondary endpoints x2 showing clinical benefit
Imo: it’s a given
There’s more to read into David’s email to me1) note that...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $100.4M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.1¢ | 1.0¢ | $60.81K | 5.737M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 37 | 16255465 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 1643984 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| ATH (ASX) Chart |